近日,跨国医疗器械公司赛默飞世尔科技(下称“赛默飞”)宣布一笔重磅收购。公司将以41亿美元现金收购Solventum的净化与过滤业务。后者是一家于去年4月从3M剥离出来的医疗保健公司。赛默飞方面认为,收购上述业务能够与公司的生物生产业务(如细胞培养基和一次性技术)高度互补。同时,对于Solventum而言,出售净化与过滤业务也将为公司带来可观的净收益,使其能够偿还债务,聚焦核心战略。41亿美元现金...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.